cerrar
Tagged with

Ethics in Artificial Intelligence: Better Prepare Now for New EU…
With upcoming EU regulation poised to have a massive impact on ethical regulations around AI in Europe, Bayer Head of Digital Transformation Saskia…

Top 7 Biotech IPOs in 2020
Following the recent news of Remegen's massive USD 515 million IPO in November 2020, we bring you the seven biggest biotech IPOs this year. Notably,…

Singapore Pharma Industry Snapshot 2020
Singapore is home to a wide range of biopharmaceutical company headquarters, many of them regional bases, and clusters. Made with Visme…

Singapore Macroeconomic & Competitiveness Snapshot 2020
Singapore is far ahead of its Asia-Pacific peers in terms of GDP per person. Made with Visme Infographic Maker Singapore was ranked…

China: Hitgen Aims to Strengthen its “Innovation Foundation”…
PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical…

Ebola Vaccine Lessons for COVID-19 & The Future of Global…
Epidemiologist John-Arne Røttingen has had a long and distinguished career in both academia and industry, including stints at Oslo, Oxford and…

Ellen Cathrine Andersen – CEO, EpiGuard
CEO Ellen Cathrine Andersen introduces Norwegian firm Epiguard’s ‘Epishuttle’ technology for transporting highly contagious patients, the…

Dennis Hens – CEO, Bulbitech
Dennis Hens, the Dutch CEO of Norwegian neuro-opthalmology device player Bulbitech, outlines the company’s journey to market, how its technology can…

Sanofi: The “Tortoise” of the COVID-19 Vaccine Race?
Sanofi CEO Paul Hudson ignited a heated debate around vaccine nationalism earlier this year when he suggested that the US, having made the biggest…

6 Key Takeaways from GSK Vaccines Head Roger Connor at FT…
During the FT Global Pharmaceutical and Biotechnology Conference last week, GSK global vaccines president Roger Connor shared some of his insights…

Ipsen CEO David Loew: Pharma Has to Play “A Wider Role” in…
Ipsen CEO David Loew took aim at the lip service often paid to the notion of ‘patient-centricity’ in pharma in conversation at the FT’s Global…

Is the USA’s Innovation Leadership Position At-Risk?
David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term sustainability. The…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here